First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma

J Pediatr Hematol Oncol. 2022 Aug 1;44(6):e948-e953. doi: 10.1097/MPH.0000000000002488. Epub 2022 May 27.

Abstract

Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here we report 3 cases with newly diagnosed, metastatic, GD2-positive ES or Ewing-like sarcoma treated with the anti-GD2 antibody dinutuximab beta in addition to standard chemotherapeutic regimens. Treatment was well-tolerated, and all patients achieved complete remission, without evidence of relapse. First-line anti-GD2 immunotherapy in patients with metastatic, GD2-positive ES or Ewing-like sarcoma represents a promising therapeutic option that warrants further clinical evaluation.

MeSH terms

  • Consolidation Chemotherapy
  • Humans
  • Neoplasm Recurrence, Local / drug therapy
  • Sarcoma* / drug therapy
  • Sarcoma, Ewing* / pathology
  • Soft Tissue Neoplasms* / drug therapy